Tot Biopharm receives China regulatory approval for a bevacizumab biosimilar and Fujifilm moves forward with plans for a Suzhou Innovation and Collaboration Center.
An industrialized center northwest of Shanghai, China, was the source of a few items of biosimilars news this week.
Tot Biopharm
Suzhou, China-based Tot Biopharm said it has been granted regulatory approval for a bevacizumab biosimilar (Pusintin) by China’s National Medical Products Administration.
Pusintin (TAB008; injectable) is now approved for the treatment of patients with advanced metastatic or recurrent nonsquamous non–small cell lung cancer and metastatic colorectal cancer.
Bevacizumab reduces tumor-supporting blood vessels by targeting vascular endothelial growth factor. Tot Pharma cited pharmaceutical studies and nonclinical and clinical studies demonstrating that Pusintin is equivalent to the reference product, Avastin.
In China, bevacizumab is also approved for treatment of glioblastoma multiforme, hepatocellular carcinoma, ovarian cancer, and cervical cancer. Tot Pharma has commercial-scale manufacturing operations in Suzhou Industrial Park.
Fujifilm Innovation Center
With the growth of biosimilar markets and the demand for more affordable drugs, the market for cell culture development services is growing in China. Biosimilars are made from living organisms, and cell cultures are necessary for development of these therapeutics.
Fujifilm Irvine Scientific, of Santa Ana, California, said it will establish an Innovation and Collaboration Center in Suzhou New District where employees can design upstream cell culture processes for customers’ biomanufacturing needs.
“In the past decade, the world has seen rapid growth in China’s biopharmaceutical, vaccine, cell and gene therapy markets. The speed of approval of biosimilar drugs and investment by the government to make more affordable drugs available to its people is accelerating that growth,” the company said in a statement. Fujifilm said the market for cell culture media is anticipated to grow at an annual rate of 20%.
“The Innovation and Collaboration Center will incorporate advanced cell culture automation and analysis into process and media development to enable highly accurate evaluation and identification of optimal upstream cell culture processes,” Fujifilm said.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international recognition procedure under the Medicines and Healthcare Products Regulatory Agency (MHRA) could expand biosimilar access within the United Kingdom, in his latest column.